Loading…
Human herpesvirus-6 viremia is not associated with poor clinical outcomes in children following allogeneic hematopoietic cell transplantation
HHV‐6 is an evolving pathogen in the field of AlloHCT. However, the impact of HHV‐6 on AlloHCT outcomes remains to be elucidated. We studied the incidence and clinical impact of HHV‐6 viremia in children following AlloHCT. One hundred consecutive children were monitored weekly by plasma PCR for the...
Saved in:
Published in: | Pediatric transplantation 2015-11, Vol.19 (7), p.737-744 |
---|---|
Main Authors: | , , , , , , , , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | cdi_FETCH-LOGICAL-c5432-2ff198e3136577e3034454dd63633ae91911ffd88dad2c01dd5eea8e11b181443 |
---|---|
cites | cdi_FETCH-LOGICAL-c5432-2ff198e3136577e3034454dd63633ae91911ffd88dad2c01dd5eea8e11b181443 |
container_end_page | 744 |
container_issue | 7 |
container_start_page | 737 |
container_title | Pediatric transplantation |
container_volume | 19 |
creator | Violago, Leah Jin, Zhezhen Bhatia, Monica Rustia, Evelyn Kung, Andrew L. Foca, Marc D. George, Diane Garvin, James H. Sosna, Jean Robinson, Chalitha Karamehmet, Esra Satwani, Prakash |
description | HHV‐6 is an evolving pathogen in the field of AlloHCT. However, the impact of HHV‐6 on AlloHCT outcomes remains to be elucidated. We studied the incidence and clinical impact of HHV‐6 viremia in children following AlloHCT. One hundred consecutive children were monitored weekly by plasma PCR for the first 180 days following AlloHCT for HHV‐6, CMV, EBV, and ADV. HHV‐6 viremia was defined as plasma PCR >1000 viral copies/mL. The median age was nine yr. Following AlloHCT, 19% (95% CI 11.3–26.7%) of patients had HHV‐6 viremia, with the highest incidence of reactivation (14/19, 73%) occurring during day +15‐day +98. The proportion of platelet engraftment by day +180 was lower in patients with HHV‐6 viremia (58%) than in those without HHV‐6 viremia (82%), p = 0.028. Delay in neutrophil and platelet engraftment was not associated with HHV‐6 viremia in multivariate analysis. Similarly, HHV‐6 viremia was not associated with TRM in multivariate analysis (p = 0.15). In summary, HHV‐6 viremia is prevalent in pediatric AlloHCT recipients. Based on our study results, we recommend that HHV‐6 PCR should only be performed on clinical suspicion. |
doi_str_mv | 10.1111/petr.12572 |
format | article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1719422738</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1719422738</sourcerecordid><originalsourceid>FETCH-LOGICAL-c5432-2ff198e3136577e3034454dd63633ae91911ffd88dad2c01dd5eea8e11b181443</originalsourceid><addsrcrecordid>eNp9kMlOHDEQhq0oUViSSx4g8jFCatJlu7djxDIgoWwiy80ydjVjcNuN7WbgIXjn9DDAMXX5q6Sv_ir9hHyAch_m-jxijvvAqoa9ItvAu67gpahfP_ZNwUGwLbKT0lVZQi1a8ZZssZqzrhKwTR5OpkF5usQ4Yrq1cUpFTWfFwSpqE_UhU5VS0FZlNHRl85KOIUSqnfVWK0fDlHUYMFHrqV5aZyJ62gfnwsr6S6rm5hI9Wj0fGVQOY7CY50mjczRH5dPolM8q2-DfkTe9cgnfP-ku-XV8dH5wUpx9W5wefDkrdCU4K1jfQ9ciB15XTYO85EJUwpia15wr7KAD6HvTtkYZpkswpkJULQJcQAtC8F3yaeM7xnAzYcpysGn9kPIYpiShgU4w1vB2Rvc2qI4hpYi9HKMdVLyXUMp1_HIdv3yMf4Y_PvlOFwOaF_Q57xmADbCyDu__YyW_H53_fDYtNjs2Zbx72VHxWtYNbyr55-tCilK0h7___pAL_g_jS6J7</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1719422738</pqid></control><display><type>article</type><title>Human herpesvirus-6 viremia is not associated with poor clinical outcomes in children following allogeneic hematopoietic cell transplantation</title><source>Wiley</source><creator>Violago, Leah ; Jin, Zhezhen ; Bhatia, Monica ; Rustia, Evelyn ; Kung, Andrew L. ; Foca, Marc D. ; George, Diane ; Garvin, James H. ; Sosna, Jean ; Robinson, Chalitha ; Karamehmet, Esra ; Satwani, Prakash</creator><creatorcontrib>Violago, Leah ; Jin, Zhezhen ; Bhatia, Monica ; Rustia, Evelyn ; Kung, Andrew L. ; Foca, Marc D. ; George, Diane ; Garvin, James H. ; Sosna, Jean ; Robinson, Chalitha ; Karamehmet, Esra ; Satwani, Prakash</creatorcontrib><description>HHV‐6 is an evolving pathogen in the field of AlloHCT. However, the impact of HHV‐6 on AlloHCT outcomes remains to be elucidated. We studied the incidence and clinical impact of HHV‐6 viremia in children following AlloHCT. One hundred consecutive children were monitored weekly by plasma PCR for the first 180 days following AlloHCT for HHV‐6, CMV, EBV, and ADV. HHV‐6 viremia was defined as plasma PCR >1000 viral copies/mL. The median age was nine yr. Following AlloHCT, 19% (95% CI 11.3–26.7%) of patients had HHV‐6 viremia, with the highest incidence of reactivation (14/19, 73%) occurring during day +15‐day +98. The proportion of platelet engraftment by day +180 was lower in patients with HHV‐6 viremia (58%) than in those without HHV‐6 viremia (82%), p = 0.028. Delay in neutrophil and platelet engraftment was not associated with HHV‐6 viremia in multivariate analysis. Similarly, HHV‐6 viremia was not associated with TRM in multivariate analysis (p = 0.15). In summary, HHV‐6 viremia is prevalent in pediatric AlloHCT recipients. Based on our study results, we recommend that HHV‐6 PCR should only be performed on clinical suspicion.</description><identifier>ISSN: 1397-3142</identifier><identifier>EISSN: 1399-3046</identifier><identifier>DOI: 10.1111/petr.12572</identifier><identifier>PMID: 26329541</identifier><language>eng</language><publisher>Denmark: Blackwell Publishing Ltd</publisher><subject>Adolescent ; Child ; Child, Preschool ; Delayed Graft Function - virology ; Female ; hematopoietic stem cell transplant ; Hematopoietic Stem Cell Transplantation ; Herpesvirus 6, Human - isolation & purification ; human herpesvirus ; Humans ; Incidence ; Infant ; Male ; Outcome Assessment (Health Care) ; pediatrics ; Postoperative Complications - diagnosis ; Postoperative Complications - epidemiology ; Prognosis ; Proportional Hazards Models ; Retrospective Studies ; Roseolovirus Infections - diagnosis ; Roseolovirus Infections - epidemiology ; Roseolovirus Infections - etiology ; Transplantation, Homologous ; Viremia - diagnosis ; Viremia - epidemiology ; Viremia - etiology ; Young Adult</subject><ispartof>Pediatric transplantation, 2015-11, Vol.19 (7), p.737-744</ispartof><rights>2015 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd</rights><rights>2015 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c5432-2ff198e3136577e3034454dd63633ae91911ffd88dad2c01dd5eea8e11b181443</citedby><cites>FETCH-LOGICAL-c5432-2ff198e3136577e3034454dd63633ae91911ffd88dad2c01dd5eea8e11b181443</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/26329541$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Violago, Leah</creatorcontrib><creatorcontrib>Jin, Zhezhen</creatorcontrib><creatorcontrib>Bhatia, Monica</creatorcontrib><creatorcontrib>Rustia, Evelyn</creatorcontrib><creatorcontrib>Kung, Andrew L.</creatorcontrib><creatorcontrib>Foca, Marc D.</creatorcontrib><creatorcontrib>George, Diane</creatorcontrib><creatorcontrib>Garvin, James H.</creatorcontrib><creatorcontrib>Sosna, Jean</creatorcontrib><creatorcontrib>Robinson, Chalitha</creatorcontrib><creatorcontrib>Karamehmet, Esra</creatorcontrib><creatorcontrib>Satwani, Prakash</creatorcontrib><title>Human herpesvirus-6 viremia is not associated with poor clinical outcomes in children following allogeneic hematopoietic cell transplantation</title><title>Pediatric transplantation</title><addtitle>Pediatr Transplantation</addtitle><description>HHV‐6 is an evolving pathogen in the field of AlloHCT. However, the impact of HHV‐6 on AlloHCT outcomes remains to be elucidated. We studied the incidence and clinical impact of HHV‐6 viremia in children following AlloHCT. One hundred consecutive children were monitored weekly by plasma PCR for the first 180 days following AlloHCT for HHV‐6, CMV, EBV, and ADV. HHV‐6 viremia was defined as plasma PCR >1000 viral copies/mL. The median age was nine yr. Following AlloHCT, 19% (95% CI 11.3–26.7%) of patients had HHV‐6 viremia, with the highest incidence of reactivation (14/19, 73%) occurring during day +15‐day +98. The proportion of platelet engraftment by day +180 was lower in patients with HHV‐6 viremia (58%) than in those without HHV‐6 viremia (82%), p = 0.028. Delay in neutrophil and platelet engraftment was not associated with HHV‐6 viremia in multivariate analysis. Similarly, HHV‐6 viremia was not associated with TRM in multivariate analysis (p = 0.15). In summary, HHV‐6 viremia is prevalent in pediatric AlloHCT recipients. Based on our study results, we recommend that HHV‐6 PCR should only be performed on clinical suspicion.</description><subject>Adolescent</subject><subject>Child</subject><subject>Child, Preschool</subject><subject>Delayed Graft Function - virology</subject><subject>Female</subject><subject>hematopoietic stem cell transplant</subject><subject>Hematopoietic Stem Cell Transplantation</subject><subject>Herpesvirus 6, Human - isolation & purification</subject><subject>human herpesvirus</subject><subject>Humans</subject><subject>Incidence</subject><subject>Infant</subject><subject>Male</subject><subject>Outcome Assessment (Health Care)</subject><subject>pediatrics</subject><subject>Postoperative Complications - diagnosis</subject><subject>Postoperative Complications - epidemiology</subject><subject>Prognosis</subject><subject>Proportional Hazards Models</subject><subject>Retrospective Studies</subject><subject>Roseolovirus Infections - diagnosis</subject><subject>Roseolovirus Infections - epidemiology</subject><subject>Roseolovirus Infections - etiology</subject><subject>Transplantation, Homologous</subject><subject>Viremia - diagnosis</subject><subject>Viremia - epidemiology</subject><subject>Viremia - etiology</subject><subject>Young Adult</subject><issn>1397-3142</issn><issn>1399-3046</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><recordid>eNp9kMlOHDEQhq0oUViSSx4g8jFCatJlu7djxDIgoWwiy80ydjVjcNuN7WbgIXjn9DDAMXX5q6Sv_ir9hHyAch_m-jxijvvAqoa9ItvAu67gpahfP_ZNwUGwLbKT0lVZQi1a8ZZssZqzrhKwTR5OpkF5usQ4Yrq1cUpFTWfFwSpqE_UhU5VS0FZlNHRl85KOIUSqnfVWK0fDlHUYMFHrqV5aZyJ62gfnwsr6S6rm5hI9Wj0fGVQOY7CY50mjczRH5dPolM8q2-DfkTe9cgnfP-ku-XV8dH5wUpx9W5wefDkrdCU4K1jfQ9ciB15XTYO85EJUwpia15wr7KAD6HvTtkYZpkswpkJULQJcQAtC8F3yaeM7xnAzYcpysGn9kPIYpiShgU4w1vB2Rvc2qI4hpYi9HKMdVLyXUMp1_HIdv3yMf4Y_PvlOFwOaF_Q57xmADbCyDu__YyW_H53_fDYtNjs2Zbx72VHxWtYNbyr55-tCilK0h7___pAL_g_jS6J7</recordid><startdate>201511</startdate><enddate>201511</enddate><creator>Violago, Leah</creator><creator>Jin, Zhezhen</creator><creator>Bhatia, Monica</creator><creator>Rustia, Evelyn</creator><creator>Kung, Andrew L.</creator><creator>Foca, Marc D.</creator><creator>George, Diane</creator><creator>Garvin, James H.</creator><creator>Sosna, Jean</creator><creator>Robinson, Chalitha</creator><creator>Karamehmet, Esra</creator><creator>Satwani, Prakash</creator><general>Blackwell Publishing Ltd</general><scope>BSCLL</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>201511</creationdate><title>Human herpesvirus-6 viremia is not associated with poor clinical outcomes in children following allogeneic hematopoietic cell transplantation</title><author>Violago, Leah ; Jin, Zhezhen ; Bhatia, Monica ; Rustia, Evelyn ; Kung, Andrew L. ; Foca, Marc D. ; George, Diane ; Garvin, James H. ; Sosna, Jean ; Robinson, Chalitha ; Karamehmet, Esra ; Satwani, Prakash</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c5432-2ff198e3136577e3034454dd63633ae91911ffd88dad2c01dd5eea8e11b181443</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2015</creationdate><topic>Adolescent</topic><topic>Child</topic><topic>Child, Preschool</topic><topic>Delayed Graft Function - virology</topic><topic>Female</topic><topic>hematopoietic stem cell transplant</topic><topic>Hematopoietic Stem Cell Transplantation</topic><topic>Herpesvirus 6, Human - isolation & purification</topic><topic>human herpesvirus</topic><topic>Humans</topic><topic>Incidence</topic><topic>Infant</topic><topic>Male</topic><topic>Outcome Assessment (Health Care)</topic><topic>pediatrics</topic><topic>Postoperative Complications - diagnosis</topic><topic>Postoperative Complications - epidemiology</topic><topic>Prognosis</topic><topic>Proportional Hazards Models</topic><topic>Retrospective Studies</topic><topic>Roseolovirus Infections - diagnosis</topic><topic>Roseolovirus Infections - epidemiology</topic><topic>Roseolovirus Infections - etiology</topic><topic>Transplantation, Homologous</topic><topic>Viremia - diagnosis</topic><topic>Viremia - epidemiology</topic><topic>Viremia - etiology</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Violago, Leah</creatorcontrib><creatorcontrib>Jin, Zhezhen</creatorcontrib><creatorcontrib>Bhatia, Monica</creatorcontrib><creatorcontrib>Rustia, Evelyn</creatorcontrib><creatorcontrib>Kung, Andrew L.</creatorcontrib><creatorcontrib>Foca, Marc D.</creatorcontrib><creatorcontrib>George, Diane</creatorcontrib><creatorcontrib>Garvin, James H.</creatorcontrib><creatorcontrib>Sosna, Jean</creatorcontrib><creatorcontrib>Robinson, Chalitha</creatorcontrib><creatorcontrib>Karamehmet, Esra</creatorcontrib><creatorcontrib>Satwani, Prakash</creatorcontrib><collection>Istex</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Pediatric transplantation</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Violago, Leah</au><au>Jin, Zhezhen</au><au>Bhatia, Monica</au><au>Rustia, Evelyn</au><au>Kung, Andrew L.</au><au>Foca, Marc D.</au><au>George, Diane</au><au>Garvin, James H.</au><au>Sosna, Jean</au><au>Robinson, Chalitha</au><au>Karamehmet, Esra</au><au>Satwani, Prakash</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Human herpesvirus-6 viremia is not associated with poor clinical outcomes in children following allogeneic hematopoietic cell transplantation</atitle><jtitle>Pediatric transplantation</jtitle><addtitle>Pediatr Transplantation</addtitle><date>2015-11</date><risdate>2015</risdate><volume>19</volume><issue>7</issue><spage>737</spage><epage>744</epage><pages>737-744</pages><issn>1397-3142</issn><eissn>1399-3046</eissn><abstract>HHV‐6 is an evolving pathogen in the field of AlloHCT. However, the impact of HHV‐6 on AlloHCT outcomes remains to be elucidated. We studied the incidence and clinical impact of HHV‐6 viremia in children following AlloHCT. One hundred consecutive children were monitored weekly by plasma PCR for the first 180 days following AlloHCT for HHV‐6, CMV, EBV, and ADV. HHV‐6 viremia was defined as plasma PCR >1000 viral copies/mL. The median age was nine yr. Following AlloHCT, 19% (95% CI 11.3–26.7%) of patients had HHV‐6 viremia, with the highest incidence of reactivation (14/19, 73%) occurring during day +15‐day +98. The proportion of platelet engraftment by day +180 was lower in patients with HHV‐6 viremia (58%) than in those without HHV‐6 viremia (82%), p = 0.028. Delay in neutrophil and platelet engraftment was not associated with HHV‐6 viremia in multivariate analysis. Similarly, HHV‐6 viremia was not associated with TRM in multivariate analysis (p = 0.15). In summary, HHV‐6 viremia is prevalent in pediatric AlloHCT recipients. Based on our study results, we recommend that HHV‐6 PCR should only be performed on clinical suspicion.</abstract><cop>Denmark</cop><pub>Blackwell Publishing Ltd</pub><pmid>26329541</pmid><doi>10.1111/petr.12572</doi><tpages>8</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1397-3142 |
ispartof | Pediatric transplantation, 2015-11, Vol.19 (7), p.737-744 |
issn | 1397-3142 1399-3046 |
language | eng |
recordid | cdi_proquest_miscellaneous_1719422738 |
source | Wiley |
subjects | Adolescent Child Child, Preschool Delayed Graft Function - virology Female hematopoietic stem cell transplant Hematopoietic Stem Cell Transplantation Herpesvirus 6, Human - isolation & purification human herpesvirus Humans Incidence Infant Male Outcome Assessment (Health Care) pediatrics Postoperative Complications - diagnosis Postoperative Complications - epidemiology Prognosis Proportional Hazards Models Retrospective Studies Roseolovirus Infections - diagnosis Roseolovirus Infections - epidemiology Roseolovirus Infections - etiology Transplantation, Homologous Viremia - diagnosis Viremia - epidemiology Viremia - etiology Young Adult |
title | Human herpesvirus-6 viremia is not associated with poor clinical outcomes in children following allogeneic hematopoietic cell transplantation |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-26T08%3A09%3A40IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Human%20herpesvirus-6%20viremia%20is%20not%20associated%20with%20poor%20clinical%20outcomes%20in%20children%20following%20allogeneic%20hematopoietic%20cell%20transplantation&rft.jtitle=Pediatric%20transplantation&rft.au=Violago,%20Leah&rft.date=2015-11&rft.volume=19&rft.issue=7&rft.spage=737&rft.epage=744&rft.pages=737-744&rft.issn=1397-3142&rft.eissn=1399-3046&rft_id=info:doi/10.1111/petr.12572&rft_dat=%3Cproquest_cross%3E1719422738%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c5432-2ff198e3136577e3034454dd63633ae91911ffd88dad2c01dd5eea8e11b181443%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1719422738&rft_id=info:pmid/26329541&rfr_iscdi=true |